# OnCo record post-transplant-lymphoproliferative-disorder (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "post-transplant-lymphoproliferative-disorder" ;
  schema:name "Post-transplant lymphoproliferative disorder (PTLD)"@en ;
  schema:alternateName "PTLD"@en, "EBV-positive PTLD"@en, "Immunodeficiency-associated lymphoproliferative disorder"@en ;
  schema:description "After an organ or stem cell transplant, the drugs that stop rejection also stop the immune system from policing Epstein-Barr virus, and infected B cells can grow into a lymphoma. The first move is to ease the immunosuppression; then the antibody rituximab, chemotherapy if needed, and, newest of all, off-the-shelf virus-specific T cells that restore the missing immune control."@en ;
  schema:url <https://onco.cc/cancers/post-transplant-lymphoproliferative-disorder/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Post-transplant_lymphoproliferative_disorder> ;
  schema:citation <https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq>, <https://doi.org/10.1016/S1470-2045(11)70300-X>, <https://doi.org/10.1200/JCO.2016.69.3564>, <https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo>, <https://doi.org/10.1111/bjh.17421> ;
  onco:tag "nci-coverage", "rare", "haematologic", "virus-associated" ;
  onco:related <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/hiv-associated-lymphoma/>, <https://onco.cc/cancers/burkitt-lymphoma/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/primary-cns-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd19/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/> ;
  onco:pathways <https://onco.cc/pathways/oncogenic-viruses/>, <https://onco.cc/pathways/antigen-presentation-immunoediting/> ;
  onco:terms <https://onco.cc/terms/ebv-term/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/terms/allogeneic-transplant/>, <https://onco.cc/terms/gvhd/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-trappe-lancet-oncol/>, <https://onco.cc/key-papers/paper-shah-br-j-haematol/> ;
  onco:pipeline <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/> ;
  onco:standardOfCare <https://onco.cc/terms/ebv-term/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/trials/ptld-1/>, <https://onco.cc/technologies/allogeneic-cell-therapy/>, <https://onco.cc/terms/ebv-term/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/terms/plasma-ebv-dna/> .